FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997934275> ?p ?o ?g. }

• W1997934275 endingPage "S15" @default.
• W1997934275 startingPage "S11" @default.
• W1997934275 abstract "Surgery is the only curative therapy for gastric cancer. In the metastatic setting the objective of treatment is to manage symptoms, improve quality of life and prolong survival, but current treatment options have limited efficacy and some of them exhibit unfavourable toxicity profiles. Fluoropyrimidine, taxanes and platinum-based regimens are used most frequently and offer a response rate of 30–50% with a median overall survival of =1 year. These discouraging data support the need for new therapeutic strategies based on targeted drugs. Trastuzumab, a monoclonal antibody against HER2, has shown survival benefits when given with chemotherapy in all setting of HER2-positive breast cancer patients. The ToGA trial, the first study evaluating the efficacy and safety of adding trastuzumab to chemotherapy in HER-2 positive advanced gastric cancer, showed a significant superiority of combination over chemotherapy alone. Based on these results trastuzumab combined with a cisplatin and fluoropyrimidine regimen appear the new reference treatment for HER-2 positive metastatic gastric cancer. Surgery is the only curative therapy for gastric cancer. In the metastatic setting the objective of treatment is to manage symptoms, improve quality of life and prolong survival, but current treatment options have limited efficacy and some of them exhibit unfavourable toxicity profiles. Fluoropyrimidine, taxanes and platinum-based regimens are used most frequently and offer a response rate of 30–50% with a median overall survival of =1 year. These discouraging data support the need for new therapeutic strategies based on targeted drugs. Trastuzumab, a monoclonal antibody against HER2, has shown survival benefits when given with chemotherapy in all setting of HER2-positive breast cancer patients. The ToGA trial, the first study evaluating the efficacy and safety of adding trastuzumab to chemotherapy in HER-2 positive advanced gastric cancer, showed a significant superiority of combination over chemotherapy alone. Based on these results trastuzumab combined with a cisplatin and fluoropyrimidine regimen appear the new reference treatment for HER-2 positive metastatic gastric cancer." @default.
• W1997934275 created "2016-06-24" @default.
• W1997934275 creator A5009130863 @default.
• W1997934275 creator A5028284107 @default.
• W1997934275 creator A5047814180 @default.
• W1997934275 creator A5056034569 @default.
• W1997934275 creator A5085152226 @default.
• W1997934275 creator A5086984759 @default.
• W1997934275 date "2010-11-01" @default.
• W1997934275 modified "2023-09-24" @default.
• W1997934275 title "Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target" @default.
• W1997934275 cites W1807105923 @default.
• W1997934275 cites W1964230131 @default.
• W1997934275 cites W1976651872 @default.
• W1997934275 cites W1977874955 @default.
• W1997934275 cites W1987009448 @default.
• W1997934275 cites W1987362747 @default.
• W1997934275 cites W1992408996 @default.
• W1997934275 cites W2036562940 @default.
• W1997934275 cites W2039254513 @default.
• W1997934275 cites W2044687869 @default.
• W1997934275 cites W2050389569 @default.
• W1997934275 cites W2051566114 @default.
• W1997934275 cites W2054390556 @default.
• W1997934275 cites W2060668988 @default.
• W1997934275 cites W2060731557 @default.
• W1997934275 cites W2108757481 @default.
• W1997934275 cites W2110444464 @default.
• W1997934275 cites W2115351494 @default.
• W1997934275 cites W2126532720 @default.
• W1997934275 cites W2130522735 @default.
• W1997934275 cites W2136701318 @default.
• W1997934275 cites W2147551134 @default.
• W1997934275 cites W2157824687 @default.
• W1997934275 cites W2167225787 @default.
• W1997934275 cites W2273629192 @default.
• W1997934275 cites W2288763477 @default.
• W1997934275 cites W4231547015 @default.
• W1997934275 cites W4231780986 @default.
• W1997934275 cites W4248204656 @default.
• W1997934275 cites W4367436653 @default.
• W1997934275 doi "https://doi.org/10.1016/s0305-7372(10)70014-1" @default.
• W1997934275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21129604" @default.
• W1997934275 hasPublicationYear "2010" @default.
• W1997934275 type Work @default.
• W1997934275 sameAs 1997934275 @default.
• W1997934275 citedByCount "77" @default.
• W1997934275 countsByYear W19979342752012 @default.
• W1997934275 countsByYear W19979342752013 @default.
• W1997934275 countsByYear W19979342752014 @default.
• W1997934275 countsByYear W19979342752015 @default.
• W1997934275 countsByYear W19979342752016 @default.
• W1997934275 countsByYear W19979342752017 @default.
• W1997934275 countsByYear W19979342752018 @default.
• W1997934275 countsByYear W19979342752019 @default.
• W1997934275 countsByYear W19979342752020 @default.
• W1997934275 countsByYear W19979342752021 @default.
• W1997934275 countsByYear W19979342752022 @default.
• W1997934275 crossrefType "journal-article" @default.
• W1997934275 hasAuthorship W1997934275A5009130863 @default.
• W1997934275 hasAuthorship W1997934275A5028284107 @default.
• W1997934275 hasAuthorship W1997934275A5047814180 @default.
• W1997934275 hasAuthorship W1997934275A5056034569 @default.
• W1997934275 hasAuthorship W1997934275A5085152226 @default.
• W1997934275 hasAuthorship W1997934275A5086984759 @default.
• W1997934275 hasConcept C121608353 @default.
• W1997934275 hasConcept C126322002 @default.
• W1997934275 hasConcept C143998085 @default.
• W1997934275 hasConcept C2775930923 @default.
• W1997934275 hasConcept C2776694085 @default.
• W1997934275 hasConcept C2779786085 @default.
• W1997934275 hasConcept C2781413609 @default.
• W1997934275 hasConcept C530470458 @default.
• W1997934275 hasConcept C71924100 @default.
• W1997934275 hasConceptScore W1997934275C121608353 @default.
• W1997934275 hasConceptScore W1997934275C126322002 @default.
• W1997934275 hasConceptScore W1997934275C143998085 @default.
• W1997934275 hasConceptScore W1997934275C2775930923 @default.
• W1997934275 hasConceptScore W1997934275C2776694085 @default.
• W1997934275 hasConceptScore W1997934275C2779786085 @default.
• W1997934275 hasConceptScore W1997934275C2781413609 @default.
• W1997934275 hasConceptScore W1997934275C530470458 @default.
• W1997934275 hasConceptScore W1997934275C71924100 @default.
• W1997934275 hasLocation W19979342751 @default.
• W1997934275 hasLocation W19979342752 @default.
• W1997934275 hasOpenAccess W1997934275 @default.
• W1997934275 hasPrimaryLocation W19979342751 @default.
• W1997934275 hasRelatedWork W1972234726 @default.
• W1997934275 hasRelatedWork W2030434439 @default.
• W1997934275 hasRelatedWork W2040689610 @default.
• W1997934275 hasRelatedWork W2050439103 @default.
• W1997934275 hasRelatedWork W2092771806 @default.
• W1997934275 hasRelatedWork W2218005127 @default.
• W1997934275 hasRelatedWork W2388730008 @default.
• W1997934275 hasRelatedWork W2401765432 @default.
• W1997934275 hasRelatedWork W2969515167 @default.
• W1997934275 hasRelatedWork W3207233484 @default.
• W1997934275 hasVolume "36" @default.

• next